Egyptian International Pharmaceutical Investments (CAI:PHAR) EV-to-Revenue : 2.18 (As of Jun. 01, 2025)

Egyptian International Pharmaceutical Investments EV-to-Revenue Chart

Egyptian International Pharmaceutical Investments Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-Revenue		Get a 7-Day Free Trial					1.76	1.22	1.64	1.51	1.84

Egyptian International Pharmaceutical Investments Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-Revenue	Get a 7-Day Free Trial															1.88	1.84	2.18	2.05	2.14

Competitive Comparison of Egyptian International Pharmaceutical Investments's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egyptian International Pharmaceutical Investments's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's EV-to-Revenue falls into.

Egyptian International Pharmaceutical Investments EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Egyptian International Pharmaceutical Investments's EV-to-Revenue for today is calculated as:

Egyptian International Pharmaceutical Investments's current Enterprise Value is E£15,287 Mil.
Egyptian International Pharmaceutical Investments's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was E£7,003 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments  (CAI:PHAR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Egyptian International Pharmaceutical Investments's PS Ratiofor today is calculated as:

Egyptian International Pharmaceutical Investments's share price for today is E£50.65.
Egyptian International Pharmaceutical Investments's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was E£47.07.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments Business Description